$AEON
AEON Biopharma, Inc.

2024 Q1 Form 10-K Financial Statement

#000183760724000015 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2022
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.649M $4.489M $13.68M
YoY Change 21.04%
% of Gross Profit
Research & Development $5.732M $6.860M $34.75M
YoY Change -37.73%
% of Gross Profit
Depreciation & Amortization $25.00K $24.00K $68.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $74.15M $28.31M $3.326M
YoY Change 4152.96% 1300.83% 71.78%
Operating Profit -$74.15M -$3.326M
YoY Change 4152.98% 71.78%
Interest Expense -$15.83M $10.42M
YoY Change -713.57% -3.43%
% of Operating Profit
Other Income/Expense, Net -$43.87M $1.655M $14.19M
YoY Change -2593.06% 39.98%
Pretax Income -$118.0M -$42.49M $10.86M
YoY Change -732267.01% -5989.28% 32.47%
Income Tax $0.00 $883.3K
% Of Pretax Income 8.13%
Net Earnings -$118.0M -$42.49M $9.980M
YoY Change 30276.69% -46089.83% 21.7%
Net Earnings / Revenue
Basic Earnings Per Share -$3.17 -$0.38
Diluted Earnings Per Share -$3.17 -$1.14 $0.18
COMMON SHARES
Basic Shares Outstanding 37.79M 37.16M 138.8M
Diluted Shares Outstanding 37.27M 138.8M

Balance Sheet

Concept 2024 Q1 2023 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.158M $67.91K
YoY Change 7495.35% -86.35%
Cash & Equivalents $1.558M $5.200M
Short-Term Investments
Other Short-Term Assets $1.064M $41.29K
YoY Change 2476.9% -87.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.498M $6.222M $109.2K
YoY Change 360.56% 5598.01% -86.93%
LONG-TERM ASSETS
Property, Plant & Equipment $307.0K $594.0K
YoY Change 37.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $279.4M
YoY Change 1.2%
Other Assets $29.00K $29.00K $0.00
YoY Change -100.0%
Total Long-Term Assets $534.0K $623.0K $279.4M
YoY Change -97.47% -99.78% 1.18%
TOTAL ASSETS
Total Short-Term Assets $2.498M $6.222M $109.2K
Total Long-Term Assets $534.0K $623.0K $279.4M
Total Assets $3.032M $6.845M $279.5M
YoY Change -85.97% -97.55% 0.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.523M $3.388M $2.621M
YoY Change 63.85% 29.28% 312.97%
Accrued Expenses $7.761M $226.9K
YoY Change 3319.85% 13.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $150.0K
YoY Change -100.0%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $15.96M $13.05M $3.881M
YoY Change 171.69% 236.23% 365.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $146.8M $6.562M
YoY Change 2137.61% -61.5%
Total Long-Term Liabilities $146.8M $6.562M
YoY Change 2137.61% -61.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.96M $13.05M $3.881M
Total Long-Term Liabilities $146.8M $6.562M
Total Liabilities $201.4M $159.9M $10.44M
YoY Change 2436.17% 1431.02% -41.59%
SHAREHOLDERS EQUITY
Retained Earnings -$591.6M -$473.6M
YoY Change 7948.28% 4901.24%
Common Stock $4.000K $4.000K
YoY Change -71.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$153.0M $269.1M
YoY Change
Total Liabilities & Shareholders Equity $3.032M $6.845M $279.5M
YoY Change -85.97% -97.55% 0.92%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2022
OPERATING ACTIVITIES
Net Income -$118.0M -$42.49M $9.980M
YoY Change 30276.69% -46089.83% 21.7%
Depreciation, Depletion And Amortization $25.00K $24.00K $68.00K
YoY Change 0.0%
Cash From Operating Activities -$8.600M -$11.02M -$981.4K
YoY Change 1278.36% 6371.69% -34.34%
INVESTING ACTIVITIES
Capital Expenditures $306.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $401.9K
YoY Change -100.15%
Cash From Investing Activities $401.9K
YoY Change -100.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000M 150.0K
YoY Change -101.93% -99.95%
NET CHANGE
Cash From Operating Activities -8.600M -11.02M -981.4K
Cash From Investing Activities 401.9K
Cash From Financing Activities 5.000M 150.0K
Net Change In Cash -3.600M -11.02M -429.5K
YoY Change -1025.03% -27547.07% -186.35%
FREE CASH FLOW
Cash From Operating Activities -$8.600M -$11.02M -$981.4K
Capital Expenditures $306.0K
Free Cash Flow -$1.287M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21257708
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001837607
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21257708
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-52556000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-60678000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
24046000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2023Q4 us-gaap Debt Instrument Measurement Input Extensible List
DebtInstrumentMeasurementInputExtensibleList
http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2022Q2 us-gaap Derivative Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://www.aeonbiopharma.com/20231231#ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 aeon Minimum Percentage Of Voting For Automatic Conversion Of Convertible Preferred Stock
MinimumPercentageOfVotingForAutomaticConversionOfConvertiblePreferredStock
0.0066
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37159600
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40021
CY2023 dei Entity Registrant Name
EntityRegistrantName
AEON Biopharma, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3940478
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
5 Park Plaza
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1750
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92614
CY2023 dei City Area Code
CityAreaCode
949
CY2023 dei Local Phone Number
LocalPhoneNumber
354-6499
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
14200000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37788858
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5158000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9746000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1064000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
92000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6222000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9838000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
332000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
431000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
262000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
475000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34000
CY2023Q4 us-gaap Assets
Assets
6845000
CY2022Q4 us-gaap Assets
Assets
10778000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3388000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7805000
CY2023Q4 aeon Accrued Clinical Trails Expenses Current
AccruedClinicalTrailsExpensesCurrent
5128000
CY2022Q4 aeon Accrued Clinical Trails Expenses Current
AccruedClinicalTrailsExpensesCurrent
2051000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
943000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1112000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3590000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
740000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
38834000
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
70866000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13049000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82574000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
60426000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
242000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1447000
CY2023Q4 aeon Contingent Consideration Liability
ContingentConsiderationLiability
104350000
CY2023Q4 aeon Forward Purchase Agreement And Derivative Liability
ForwardPurchaseAgreementAndDerivativeLiability
41043000
CY2023Q4 us-gaap Liabilities
Liabilities
159889000
CY2022Q4 us-gaap Liabilities
Liabilities
143242000
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44666035
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
21257708
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
141920000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
137949000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
207450050
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37159600
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138848177
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37159600
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138825356
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
381264000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187348000
CY2023Q4 aeon Subscription Receivables
SubscriptionReceivables
-60710000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-473602000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-474839000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
22821
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
23000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-153044000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-287500000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
17087000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-153044000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-270413000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6845000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10778000
us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9841000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9949000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13675000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19803000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13243000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34754000
aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-52750000
us-gaap Operating Expenses
OperatingExpenses
29644000
us-gaap Operating Expenses
OperatingExpenses
-29558000
CY2022 us-gaap Operating Expenses
OperatingExpenses
48429000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29644000
us-gaap Operating Income Loss
OperatingIncomeLoss
29558000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-48429000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-19359000
CY2022 aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-4416000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2318000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
11789000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
8366000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
114000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
536000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
289000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31034000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5512000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4127000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60678000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
24046000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52556000
aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
-60678000
aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
24046000
CY2022 aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
-52556000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-270413000
us-gaap Net Income Loss
NetIncomeLoss
-60678000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3235000
aeon Stockholders Equity Period Increase Decrease Through Debit Extinguishment Due To Warrant Modification
StockholdersEquityPeriodIncreaseDecreaseThroughDebitExtinguishmentDueToWarrantModification
17036000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-310820000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-180856000
us-gaap Net Income Loss
NetIncomeLoss
24046000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3766000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-153044000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-223824000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-52556000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5967000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-270413000
us-gaap Profit Loss
ProfitLoss
-60678000
us-gaap Profit Loss
ProfitLoss
24046000
CY2022 us-gaap Profit Loss
ProfitLoss
-52556000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000
CY2022 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
331000
us-gaap Share Based Compensation
ShareBasedCompensation
3235000
us-gaap Share Based Compensation
ShareBasedCompensation
3766000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5892000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-19359000
CY2022 aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-4416000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2318000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
11789000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
8366000
aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-52750000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
693000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
66000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4342000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6613000
aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
4736000
aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-2204000
CY2022 aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-105000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
28000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-3000
CY2022 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
174000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21745000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26081000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35584000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
306000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-306000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14000000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
44500000
CY2022 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
3992000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14000000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40508000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7745000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26081000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4618000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5128000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9746000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5200000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-473600000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., Ltd. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See <a href="#Note7_Commitment_Contingencies"><span style="font-style:normal;font-weight:normal;">Note 7 Commitments and Contingencies</span></a> for a discussion of the Daewoong Agreement.</p>
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
170000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
332000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
431000
CY2023 us-gaap Legal Fees
LegalFees
1867000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
569000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
278000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
257000
CY2023Q4 aeon Third Party Usage Liabilities Current
ThirdPartyUsageLiabilitiesCurrent
33000
CY2022Q4 aeon Third Party Usage Liabilities Current
ThirdPartyUsageLiabilitiesCurrent
202000
CY2023Q4 aeon Remaining Other Accrued Liabilities
RemainingOtherAccruedLiabilities
843000
CY2022Q4 aeon Remaining Other Accrued Liabilities
RemainingOtherAccruedLiabilities
281000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3590000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
740000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52556000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60678000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
24046000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38818536
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31294609
CY2023Q3 aeon Number Of Shares To Be Received Prior To Merger
NumberOfSharesToBeReceivedPriorToMerger
2.328
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31200000
aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
19400000
CY2022 aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
4400000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
111000000
CY2022Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
131300000
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
342011
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.3097
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
800000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-8400000
CY2023Q2 aeon Number Of Additional Shares To Be Issued
NumberOfAdditionalSharesToBeIssued
16000000
CY2023Q2 aeon Threshold Increase In Episodic Migraine Contingent Consideration Shares
ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares
11000000
CY2023Q2 aeon Number Of Chronic Migraine Contingent Consideration Shares By Increase In Episodic Migraine Contingent Consideration Shares
NumberOfChronicMigraineContingentConsiderationSharesByIncreaseInEpisodicMigraineContingentConsiderationShares
0
CY2023Q2 aeon Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares
NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares
0
CY2023Q2 aeon Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares
ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares
1000000
CY2023Q2 aeon Minimum Number Of Chronic Migraine Contingent Consideration Shares After Reduction
MinimumNumberOfChronicMigraineContingentConsiderationSharesAfterReduction
0
aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-52800000
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
292000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
292000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
278000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
278000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
262000
CY2023Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y10M24D
CY2023Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
us-gaap Operating Lease Cost
OperatingLeaseCost
153000
us-gaap Operating Lease Cost
OperatingLeaseCost
122000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
279000
us-gaap Operating Lease Payments
OperatingLeasePayments
180000
us-gaap Operating Lease Payments
OperatingLeasePayments
129000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
248000
CY2023Q3 aeon Deferred Underwriting Fee
DeferredUnderwritingFee
1250000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
271000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
296000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
123000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1647000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5303000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
12230000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
13727000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28613000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20131000
CY2023Q4 aeon Deferred Tax Assets Leasing Liability
DeferredTaxAssetsLeasingLiability
83000
CY2022Q4 aeon Deferred Tax Assets Leasing Liability
DeferredTaxAssetsLeasingLiability
157000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
23000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
32000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
11264000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6387000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54131000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46156000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53978000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45929000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
153000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
227000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
75000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
89000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
78000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
138000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
153000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
227000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 aeon Effective Income Tax Rate Reconciliation Convertible Notes
EffectiveIncomeTaxRateReconciliationConvertibleNotes
-0.111
CY2022 aeon Effective Income Tax Rate Reconciliation Convertible Notes
EffectiveIncomeTaxRateReconciliationConvertibleNotes
-0.018
CY2023 aeon Effective Income Tax Rate Reconciliation Contingent Consideration
EffectiveIncomeTaxRateReconciliationContingentConsideration
0.302
CY2023 aeon Effective Income Tax Rate Reconciliation Forward Purchase Agreements
EffectiveIncomeTaxRateReconciliationForwardPurchaseAgreements
-0.115
CY2023 aeon Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
0.013
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.020
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.005
CY2023 aeon Effective Income Tax Rate Reconciliation Officers Compensation
EffectiveIncomeTaxRateReconciliationOfficersCompensation
-0.055
CY2023 aeon Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
-0.079
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.145
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.187
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11061000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7270000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3609000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3791000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14670000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11061000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14700000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11100000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44666035
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44666035
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
21257708
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
141920000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
137949000
CY2023 aeon Number Of Votes For Each Share Of Common Stock Into Which Preferred Stock Could Be Converted
NumberOfVotesForEachShareOfCommonStockIntoWhichPreferredStockCouldBeConverted
1
CY2023Q4 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2023Q4 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
7.3097
CY2023 aeon Minimum Net Proceeds From Sale Of Common Stock In Underwritten Public Offering For Automatic Conversion Of Convertible Preferred Stock
MinimumNetProceedsFromSaleOfCommonStockInUnderwrittenPublicOfferingForAutomaticConversionOfConvertiblePreferredStock
50000000
CY2023 aeon Public Offering Price Per Share As Percentage Of Then Effective Per Share
PublicOfferingPricePerShareAsPercentageOfThenEffectivePerShare
0.714286
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
342011
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.3097
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
207450050
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138848177
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138825356
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q3 aeon Number Of Shares To Be Received Prior To Merger
NumberOfSharesToBeReceivedPriorToMerger
2.328
CY2023Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37159600
CY2023 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
38876675
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
59178609
CY2023Q3 aeon Share Based Compensation Arrangement By Share Based Payment Award Lock Up Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardLockUpTerm
P1Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.57
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.47
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.61
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.041
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0187
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0392
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001837607-24-000015-index-headers.html Edgar Link pending
0001837607-24-000015-index.html Edgar Link pending
0001837607-24-000015.txt Edgar Link pending
0001837607-24-000015-xbrl.zip Edgar Link pending
aeon-20231231.xsd Edgar Link pending
aeon-20231231x10k.htm Edgar Link pending
aeon-20231231x10k006.jpg Edgar Link pending
aeon-20231231xex10d11.htm Edgar Link pending
aeon-20231231xex31d1.htm Edgar Link pending
aeon-20231231xex31d2.htm Edgar Link pending
aeon-20231231xex32d1.htm Edgar Link pending
aeon-20231231xex32d2.htm Edgar Link pending
aeon-20231231xex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
aeon-20231231_cal.xml Edgar Link unprocessable
aeon-20231231_def.xml Edgar Link unprocessable
aeon-20231231_lab.xml Edgar Link unprocessable
aeon-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aeon-20231231x10k_htm.xml Edgar Link completed